vs
Claritev Corp（CTEV）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Claritev Corp的季度营收约是再鼎医药的1.9倍（$246.6M vs $127.1M），再鼎医药同比增速更快（17.1% vs 6.2%），Claritev Corp自由现金流更多（$36.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.5%）
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CTEV vs ZLAB — 直观对比
营收规模更大
CTEV
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出10.9%
6.2%
自由现金流更多
CTEV
多$63.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.6M | $127.1M |
| 净利润 | $-80.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -3.1% | -54.6% |
| 净利率 | -32.7% | — |
| 营收同比 | 6.2% | 17.1% |
| 净利润同比 | 41.6% | — |
| 每股收益（稀释后） | $-4.88 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTEVZLAB
| Q4 25 | $246.6M | $127.1M | ||
| Q3 25 | $246.0M | $115.4M | ||
| Q2 25 | $241.6M | $109.1M | ||
| Q1 25 | $231.3M | $105.7M | ||
| Q4 24 | $232.1M | $108.5M | ||
| Q3 24 | $230.5M | $101.8M | ||
| Q2 24 | $233.5M | $100.1M | ||
| Q1 24 | $234.5M | $87.1M |
净利润CTEVZLAB
| Q4 25 | $-80.6M | — | ||
| Q3 25 | $-69.8M | $-36.0M | ||
| Q2 25 | $-62.6M | $-40.7M | ||
| Q1 25 | $-71.3M | $-48.4M | ||
| Q4 24 | $-138.0M | — | ||
| Q3 24 | $-391.4M | $-41.7M | ||
| Q2 24 | $-576.7M | $-80.3M | ||
| Q1 24 | $-539.7M | $-53.5M |
毛利率CTEVZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CTEVZLAB
| Q4 25 | -3.1% | -54.6% | ||
| Q3 25 | 4.1% | -42.3% | ||
| Q2 25 | 6.9% | -50.3% | ||
| Q1 25 | 4.2% | -53.3% | ||
| Q4 24 | -17.8% | -62.6% | ||
| Q3 24 | -146.7% | -66.6% | ||
| Q2 24 | -224.4% | -76.0% | ||
| Q1 24 | -207.4% | -80.7% |
净利率CTEVZLAB
| Q4 25 | -32.7% | — | ||
| Q3 25 | -28.4% | -31.2% | ||
| Q2 25 | -25.9% | -37.3% | ||
| Q1 25 | -30.8% | -45.8% | ||
| Q4 24 | -59.4% | — | ||
| Q3 24 | -169.8% | -40.9% | ||
| Q2 24 | -247.0% | -80.2% | ||
| Q1 24 | -230.1% | -61.4% |
每股收益（稀释后）CTEVZLAB
| Q4 25 | $-4.88 | $-0.05 | ||
| Q3 25 | $-4.23 | $-0.03 | ||
| Q2 25 | $-3.81 | $-0.04 | ||
| Q1 25 | $-4.38 | $-0.04 | ||
| Q4 24 | $-8.49 | $-0.09 | ||
| Q3 24 | $-24.25 | $-0.04 | ||
| Q2 24 | $-35.78 | $-0.08 | ||
| Q1 24 | $-33.40 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.8M | $689.6M |
| 总债务越低越好 | $4.6B | — |
| 股东权益账面价值 | $-173.9M | $715.5M |
| 总资产 | $4.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTEVZLAB
| Q4 25 | $16.8M | $689.6M | ||
| Q3 25 | $39.2M | $717.2M | ||
| Q2 25 | $56.4M | $732.2M | ||
| Q1 25 | $23.1M | $757.3M | ||
| Q4 24 | $16.8M | $779.7M | ||
| Q3 24 | $86.6M | $616.1M | ||
| Q2 24 | $48.8M | $630.0M | ||
| Q1 24 | $58.7M | $650.8M |
总债务CTEVZLAB
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
股东权益CTEVZLAB
| Q4 25 | $-173.9M | $715.5M | ||
| Q3 25 | $-101.8M | $759.9M | ||
| Q2 25 | $-39.9M | $791.7M | ||
| Q1 25 | $14.8M | $810.8M | ||
| Q4 24 | $84.0M | $840.9M | ||
| Q3 24 | $207.6M | $667.7M | ||
| Q2 24 | $603.4M | $704.2M | ||
| Q1 24 | $1.2B | $762.2M |
总资产CTEVZLAB
| Q4 25 | $4.9B | $1.2B | ||
| Q3 25 | $5.0B | $1.2B | ||
| Q2 25 | $5.1B | $1.2B | ||
| Q1 25 | $5.1B | $1.2B | ||
| Q4 24 | $5.2B | $1.2B | ||
| Q3 24 | $5.3B | $985.3M | ||
| Q2 24 | $5.7B | $987.4M | ||
| Q1 24 | $6.4B | $988.4M |
负债/权益比CTEVZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $36.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 14.8% | -21.0% |
| 资本支出强度资本支出/营收 | 12.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CTEVZLAB
| Q4 25 | $66.3M | $-26.0M | ||
| Q3 25 | $19.9M | $-32.0M | ||
| Q2 25 | $61.2M | $-31.0M | ||
| Q1 25 | $-30.1M | $-61.7M | ||
| Q4 24 | $-33.4M | $-55.8M | ||
| Q3 24 | $72.8M | $-26.8M | ||
| Q2 24 | $18.5M | $-42.2M | ||
| Q1 24 | $49.7M | $-90.1M |
自由现金流CTEVZLAB
| Q4 25 | $36.4M | $-26.7M | ||
| Q3 25 | $-16.3M | $-35.0M | ||
| Q2 25 | $36.6M | $-33.9M | ||
| Q1 25 | $-68.9M | $-63.2M | ||
| Q4 24 | $-63.8M | $-58.4M | ||
| Q3 24 | $41.1M | $-28.2M | ||
| Q2 24 | $-7.0M | $-42.9M | ||
| Q1 24 | $19.2M | $-91.1M |
自由现金流率CTEVZLAB
| Q4 25 | 14.8% | -21.0% | ||
| Q3 25 | -6.6% | -30.4% | ||
| Q2 25 | 15.2% | -31.1% | ||
| Q1 25 | -29.8% | -59.9% | ||
| Q4 24 | -27.5% | -53.8% | ||
| Q3 24 | 17.8% | -27.7% | ||
| Q2 24 | -3.0% | -42.9% | ||
| Q1 24 | 8.2% | -104.5% |
资本支出强度CTEVZLAB
| Q4 25 | 12.1% | 0.5% | ||
| Q3 25 | 14.7% | 2.6% | ||
| Q2 25 | 10.2% | 2.6% | ||
| Q1 25 | 16.8% | 1.5% | ||
| Q4 24 | 13.1% | 2.4% | ||
| Q3 24 | 13.8% | 1.3% | ||
| Q2 24 | 10.9% | 0.7% | ||
| Q1 24 | 13.0% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTEV
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
